Toggle navigation
About Us
Portfolio
News
Contact Us
Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.
Recent News
09/06/2023
Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
READ MORE
09/05/2023
C4 Therapeutics Announces Chief Financial Officer Succession
READ MORE
08/15/2023
Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
READ MORE
08/08/2023
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
READ MORE
←
1
2
3
4
5
6
7
8
...
53
→
PORTFOLIO HIGHLIGHTS
Contact Us
Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131
Submit
4837,4748,4815,4823,4811,4819,4822,4748,4772,4748,4789,4811,4830,4819,4815,4760,4792,4760,4791,4825,4828,4817,4811,4824,4778,4825,4831,4830,4822,4825,4825,4821,4760,4813,4825,4823,4748,4758,4748,4829,4831,4812,4820,4815,4813,4830,4748,4772,4748,4781,4825,4824,4830,4811,4813,4830,4746,4784,4825,4828,4823,4748,4839
©2021 LIGHTCHAIN CAPITAL, LLC All Rights Reserved |
Privacy Policy
Website by
Tidal Media Group